Cargando…
The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
The cardiac safety of cetuximab, particularly as single approach, has not been investigated extensively. This trial was designed to evaluate the cardiac safety of cetuximab as salvage monotherapy in Chinese chemotherapy-refractory metastatic colorectal cancer (mCRC) patients. Cetuximab was administr...
Autores principales: | Tang, Xue-Miao, Chen, Hao, Liu, Yu, Huang, Bin-Lian, Zhang, Xiu-Quan, Yuan, Jian-Mei, He, Xia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279106/ https://www.ncbi.nlm.nih.gov/pubmed/28099361 http://dx.doi.org/10.1097/MD.0000000000005946 |
Ejemplares similares
-
Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis
por: Bai, Long, et al.
Publicado: (2016) -
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab
por: Basso, Michele, et al.
Publicado: (2016) -
Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell
por: Yang, Xiaohui, et al.
Publicado: (2020) -
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017) -
Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)